MX2017013154A - Conjugados anticuerpo-farmaco de sitio especifico. - Google Patents
Conjugados anticuerpo-farmaco de sitio especifico.Info
- Publication number
- MX2017013154A MX2017013154A MX2017013154A MX2017013154A MX2017013154A MX 2017013154 A MX2017013154 A MX 2017013154A MX 2017013154 A MX2017013154 A MX 2017013154A MX 2017013154 A MX2017013154 A MX 2017013154A MX 2017013154 A MX2017013154 A MX 2017013154A
- Authority
- MX
- Mexico
- Prior art keywords
- site
- specific antibody
- drug conjugates
- amino acid
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Se describen conjugados anticuerpo-fármaco de sitio específico, en particular conjugados que comprenden pirrolobenzodiazepinas (PBD) que tienen un grupo protector lábil en forma de un ligador. El sitio de conjugación, junto con la modificación del resto de anticuerpo, permite una mejora en la seguridad y la eficacia del ADC.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1506393.6A GB201506393D0 (en) | 2015-04-15 | 2015-04-15 | Site-specific antibody-drug conjugates |
PCT/EP2016/058371 WO2016166299A1 (en) | 2015-04-15 | 2016-04-15 | Site-specific antibody-drug conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017013154A true MX2017013154A (es) | 2018-02-21 |
Family
ID=53333825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017013154A MX2017013154A (es) | 2015-04-15 | 2016-04-15 | Conjugados anticuerpo-farmaco de sitio especifico. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20180125994A1 (es) |
EP (1) | EP3283118A1 (es) |
JP (1) | JP2018511628A (es) |
KR (1) | KR20170137115A (es) |
CN (1) | CN107683146A (es) |
AU (1) | AU2016249877A1 (es) |
BR (1) | BR112017022256A2 (es) |
CA (1) | CA2981920A1 (es) |
GB (1) | GB201506393D0 (es) |
MX (1) | MX2017013154A (es) |
WO (1) | WO2016166299A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11160872B2 (en) | 2017-02-08 | 2021-11-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
DK3579883T3 (da) | 2017-02-08 | 2021-09-06 | Adc Therapeutics Sa | Pyrrolobenzodiazepin-antistofkonjugater |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
CN110582505B (zh) | 2017-04-18 | 2021-04-02 | 免疫医疗有限公司 | 吡咯并苯并二氮杂*缀合物 |
US20200129638A1 (en) * | 2017-04-20 | 2020-04-30 | Adc Therapeutics Sa | Combination therapy with an anti-psma antibody-drug conjugate |
CA3057744A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-cd25 antibody-drug conjugate |
JP2020523384A (ja) | 2017-06-14 | 2020-08-06 | アーデーセー セラピューティクス ソシエテ アノニム | 抗cd25 adcを投与するための投与レジメ |
SI3668874T1 (sl) | 2017-08-18 | 2022-04-29 | Medimmune Limited | Pirolobenzodiazepinski konjugati |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
GB201820725D0 (en) | 2018-12-19 | 2019-01-30 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine resistance |
EP3899048A1 (en) | 2018-12-19 | 2021-10-27 | ADC Therapeutics SA | Pyrrolobenzodiazepine resistance |
ES2930295T3 (es) * | 2019-03-29 | 2022-12-09 | Medimmune Ltd | Compuestos y conjugados de los mismos |
GB201908128D0 (en) | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9908226A (pt) * | 1998-02-25 | 2000-10-24 | Lexigen Pharm Corp | Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo |
EP1817341A2 (en) * | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
JP5889181B2 (ja) * | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
US20130330350A1 (en) * | 2010-11-09 | 2013-12-12 | Medimmune, Llc | Antibody Scaffold For Homogenous Conjugation |
ES2680153T3 (es) * | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas |
JP6270859B2 (ja) * | 2012-10-12 | 2018-01-31 | エイディーシー・セラピューティクス・エス・アー・エール・エルAdc Therapeutics Sarl | ピロロベンゾジアゼピン−抗体結合体 |
SG11201601375VA (en) * | 2013-08-28 | 2016-03-30 | Stemcentrx Inc | Engineered anti-dll3 conjugates and methods of use |
-
2015
- 2015-04-15 GB GBGB1506393.6A patent/GB201506393D0/en not_active Ceased
-
2016
- 2016-04-15 AU AU2016249877A patent/AU2016249877A1/en not_active Abandoned
- 2016-04-15 BR BR112017022256A patent/BR112017022256A2/pt not_active Application Discontinuation
- 2016-04-15 CA CA2981920A patent/CA2981920A1/en not_active Abandoned
- 2016-04-15 CN CN201680022066.8A patent/CN107683146A/zh active Pending
- 2016-04-15 KR KR1020177030351A patent/KR20170137115A/ko unknown
- 2016-04-15 EP EP16716583.6A patent/EP3283118A1/en not_active Withdrawn
- 2016-04-15 JP JP2017553879A patent/JP2018511628A/ja active Pending
- 2016-04-15 WO PCT/EP2016/058371 patent/WO2016166299A1/en active Application Filing
- 2016-04-15 MX MX2017013154A patent/MX2017013154A/es unknown
- 2016-04-15 US US15/566,411 patent/US20180125994A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20180125994A1 (en) | 2018-05-10 |
CA2981920A1 (en) | 2016-10-20 |
EP3283118A1 (en) | 2018-02-21 |
GB201506393D0 (en) | 2015-05-27 |
JP2018511628A (ja) | 2018-04-26 |
CN107683146A (zh) | 2018-02-09 |
WO2016166299A1 (en) | 2016-10-20 |
BR112017022256A2 (pt) | 2018-07-31 |
AU2016249877A1 (en) | 2017-10-26 |
KR20170137115A (ko) | 2017-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017013154A (es) | Conjugados anticuerpo-farmaco de sitio especifico. | |
ZA201706745B (en) | Site-specific antibody-drug conjugates | |
MX2017013171A (es) | Conjugados anticuerpo-farmaco de sitio especifico. | |
MX2019009427A (es) | Conjugados de pirrolobenzodiazepinas y anticuerpos. | |
ZA201805336B (en) | Amanitin conjugates | |
MX2019010804A (es) | Compuestos de benzazepina, conjugados y usos de los mismos. | |
MX2016016515A (es) | Derivados de auristatina y conjugados de los mismos. | |
PH12019501056A1 (en) | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers | |
BR112016004242A2 (pt) | métodos para conjugação sítio-específica de anticorpos e composições | |
ZA201903062B (en) | Amanitin antibody conjugates | |
PH12018500693A1 (en) | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | |
MX2016007865A (es) | Peptidos citotoxicos y conjugados de los mismos. | |
EP3411074A4 (en) | SPECIFIC, IMMUNOCONJUGUATED CONJUGATION LINKS SPECIFIC THEREOF, METHODS OF MAKING AND USES OF SAID CONJUGATES THEREOF | |
MX2019005879A (es) | Enlazadores que contienen peptido para conjugados anticuerpo-farmaco. | |
PH12015501000A1 (en) | Anti-notch3 antibodies and antibody-drug conjugates | |
WO2014134483A3 (en) | Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents | |
IN2015DN02577A (es) | ||
PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
ZA202001747B (en) | Psma-targeting amanitin conjugates | |
EA202091161A1 (ru) | Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения | |
MX2016013704A (es) | Conjugado farmaco-anticuerpo igf-1r y su uso para el tratamiento contra el cancer. | |
WO2014134457A3 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
WO2018053552A3 (en) | Isoquinolidinobenzodiazepines | |
CY1123525T1 (el) | Μορια δεσμευσης ειδικα για asct2 και χρησεις αυτων | |
EP3775186A4 (en) | ECTONUCLEOTIDE PYROPHOSPHATE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND THEIR USES |